Noninvasive Neuromodulation in the Management of Post-COVID Musculoskeletal Pain
NCT ID: NCT06723821
Last Updated: 2025-06-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
40 participants
INTERVENTIONAL
2024-12-15
2025-11-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The post-Covid syndrome is a problem that affects a significant number of people in the world. Among the most common symptoms is pain, and although there is no specific data on neuropathic pain and Covid, due to under-diagnosis, they may be closely related.
Non-invasive neuromodulation acts on the Central Nervous System through the bioelectrical stimulation of nervous tissue and modulation of the system nervous, and can be useful in acute, chronic and musculosqueletal pain, and in symptoms such as stress, anxiety and sleep disturbances.
The objective of this clinical trial is to assess the efficacy of non-invasive neuromodulation in the treatment of post-Covid musculoskeletal pain. Subjects will be randomly divided into two groups: an experimental group in which non-invasive neuromodulation will be applied and a sham group to which it will be applied off. The variables to be studied before, during and after treatment will be neuropathic pain with the DN4 questionnaire, pain intensity with the EVA scale, sleep quality with the Pittsburgh Sleep Quality Index, level of stress and anxiety with the HADS questionnaire and quality of life with the SF12.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Analysis of Neuromodulation as a Complementary Treatment to Evidence-based Clinical Intervention in Subjects With Musculoskeletal Pathology of the Upper Limb: a Double-blind Randomized Clinical Trial
NCT07165392
Neural Tensioner Exercise on Conditioned Pain Modulation
NCT02816060
Efficacy of Myofascial Induction as a Manual Therapy Technique in Patients With Anxiety
NCT04826302
Hypoalgesic Effect of Neural Mobilization Versus Ibuprofen Pharmacologic Treatment
NCT02593721
Treatment of Myofascial Pain Syndrome With Lidocaine Injection and Physical Therapy.
NCT01250184
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Neuromodulation experimental group
The total number of sessions to be carried out on each patient will be 12 sessions, spread over 4 weeks.
The frequency will be 3 times a week. Each session with NESA microcurrents will last 60 minutes.
Neuromodulation group
During the 12 sessions of which the treatment consists in applying 60 minutes of microcurrent in low intensity.
Neuromodulation sham group
The total number of sessions to be carried out on each patient will be 12 sessions, spread over 4 weeks.
The frequency will be 3 times a week. Each session with NESA microcurrents will last 60 minutes.The treatment will be applied with a placebo device that does not emit microcurrent but that has the same function
Neuromodulation sham group
During the 12 sessions of which the treatment consists in applying 60 minutes of sham microcurrent in low intensity.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Neuromodulation group
During the 12 sessions of which the treatment consists in applying 60 minutes of microcurrent in low intensity.
Neuromodulation sham group
During the 12 sessions of which the treatment consists in applying 60 minutes of sham microcurrent in low intensity.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Present musculoskeletal pain in the last 3 months.
* Age between 18 to 65 years old.
* Score equal or superior to 4 in DN4 scale.
Exclusion Criteria
* Present musculoskeletal pain with more than 3 months of evolution.
* Pregnant women
* Present of vascular alterations, malignancy, thrombophlebitis or fever.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Alcala
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof. Dr. Daniel Pecos Martín
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Daniel Pecos-Martin, PhD
Role: STUDY_DIRECTOR
Alcala University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centro Investigación Fisioterapia y Dolor
Alcalá de Henares, Madrid, Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CEIM/2022/6/121
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.